Tryptamine Therapeutics Limited (ASX:TYP)
Australia · Delayed Price · Currency is AUD 0.0350
+0.0010 (2.94%)
At close: Aug 14, 2025, 4:00 PM AEST
Tryptamine Therapeutics Revenue
In the fiscal year ending June 30, 2024, Tryptamine Therapeutics had annual revenue of 1.33M AUD.
Revenue
1.33M
Revenue Growth
n/a
P/S Ratio
37.96
Revenue / Employee
n/a
Employees
n/a
Market Cap
50.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 1.33M | - | - |
| Aug 31, 2023 | - | - | - |
| Aug 31, 2022 | - | - | - |
| Aug 31, 2021 | - | - | - |
| Aug 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 24.61B |
| Pro Medicus | 184.58M |
| Cochlear | 2.31B |
| Sonic Healthcare | 9.33B |
| Ramsay Health Care | 17.12B |
| Telix Pharmaceuticals | 783.21M |
| Ansell | 3.00B |
| Mesoblast | 9.16M |